Akoya Biosciences, Inc. SEC Filings

Akoya Biosciences, Inc. (AKYA) – Form 4 insider filing dated 10 Jul 2025 details equity transactions by Chief Business Officer Dr. Niro Ramachandran that occurred upon the 8 Jul 2025 closing of the company’s merger with Quanterix Corporation.

Key points

• The merger converted every AKYA share into 0.1461 Quanterix (QTRX) shares plus $0.38 cash ("Per Share Merger Consideration").
• The insider executed a cashless exercise of 62,566 options at a $0.9087 strike (Code J), briefly lifting direct ownership to 324,703 shares before conversion.
• Subsequent dispositions included 42,148 shares (Code F) for withholding and 151,930 common shares plus 130,625 unvested RSUs surrendered under the merger (Code J). Final AKYA common stock balance: 0 shares.
• High-strike employee options totaling 160,000 shares (strikes $5.35–$12.30) were automatically terminated for no consideration.

Post-transaction, Akoya operates as a wholly owned subsidiary of Quanterix; future value for former Akoya holders rests in QTRX stock and the stated cash component.

Form 4 highlights the final disposition of Akoya Biosciences, Inc. (AKYA) equity held by Chief Legal Officer Jennifer Kamocsay following the 8 July 2025 closing of the company’s merger with Quanterix Corporation.

• All AKYA common shares outstanding were converted into the right to receive 0.1461 share of Quanterix common stock plus $0.38 in cash per AKYA share (subject to potential adjustments).
• The reporting person’s 16,772 directly-held AKYA shares and 162,500 unvested RSUs were reported as dispositions under transaction code “J”.
• Two outstanding employee stock-option grants for 75,000 shares at $7.60 and 70,000 shares at $5.35 were accelerated and subsequently cancelled for no consideration because their exercise prices were equal to or above the per-share merger consideration.
• After the transactions, the filing shows 0 AKYA securities remaining beneficially owned; AKYA is now a wholly owned subsidiary of Quanterix.

The filing is procedural, documenting equity conversion mechanics rather than open-market trading, and confirms that the merger has formally closed and that AKYA equity has ceased to trade independently.

Form 4 highlights the final disposition of Akoya Biosciences, Inc. (AKYA) equity held by Chief Legal Officer Jennifer Kamocsay following the 8 July 2025 closing of the company’s merger with Quanterix Corporation.

• All AKYA common shares outstanding were converted into the right to receive 0.1461 share of Quanterix common stock plus $0.38 in cash per AKYA share (subject to potential adjustments).
• The reporting person’s 16,772 directly-held AKYA shares and 162,500 unvested RSUs were reported as dispositions under transaction code “J”.
• Two outstanding employee stock-option grants for 75,000 shares at $7.60 and 70,000 shares at $5.35 were accelerated and subsequently cancelled for no consideration because their exercise prices were equal to or above the per-share merger consideration.
• After the transactions, the filing shows 0 AKYA securities remaining beneficially owned; AKYA is now a wholly owned subsidiary of Quanterix.

The filing is procedural, documenting equity conversion mechanics rather than open-market trading, and confirms that the merger has formally closed and that AKYA equity has ceased to trade independently.

Form 4 overview: On 07/10/2025, director Matthew Winkler reported the automatic disposition of 984,513 Akoya Biosciences (AKYA) common shares on 07/08/2025 under transaction code J. The shares were converted pursuant to the Amended and Restated Agreement and Plan of Merger dated 04/28/2025, whereby Akoya merged with a wholly owned subsidiary of Quanterix Corporation and became its wholly owned subsidiary.

Under the merger terms, each Akoya share was exchanged for 0.1461 Quanterix share plus $0.38 in cash, subject to potential adjustment. Following the closing, Winkler now reports zero AKYA shares beneficially owned.

The filing also discloses the cancellation of 153,731 stock options with strike prices between $2.01 and $21.95 that were at or above the per-share merger consideration; these options were terminated for no consideration.

No open-market trades, pricing data, or new financial metrics are included—this is a procedural disclosure linked solely to the completed merger.

Form 4 overview: On 07/10/2025, director Matthew Winkler reported the automatic disposition of 984,513 Akoya Biosciences (AKYA) common shares on 07/08/2025 under transaction code J. The shares were converted pursuant to the Amended and Restated Agreement and Plan of Merger dated 04/28/2025, whereby Akoya merged with a wholly owned subsidiary of Quanterix Corporation and became its wholly owned subsidiary.

Under the merger terms, each Akoya share was exchanged for 0.1461 Quanterix share plus $0.38 in cash, subject to potential adjustment. Following the closing, Winkler now reports zero AKYA shares beneficially owned.

The filing also discloses the cancellation of 153,731 stock options with strike prices between $2.01 and $21.95 that were at or above the per-share merger consideration; these options were terminated for no consideration.

No open-market trades, pricing data, or new financial metrics are included—this is a procedural disclosure linked solely to the completed merger.

Form 4 overview: On 07/10/2025, director Matthew Winkler reported the automatic disposition of 984,513 Akoya Biosciences (AKYA) common shares on 07/08/2025 under transaction code J. The shares were converted pursuant to the Amended and Restated Agreement and Plan of Merger dated 04/28/2025, whereby Akoya merged with a wholly owned subsidiary of Quanterix Corporation and became its wholly owned subsidiary.

Under the merger terms, each Akoya share was exchanged for 0.1461 Quanterix share plus $0.38 in cash, subject to potential adjustment. Following the closing, Winkler now reports zero AKYA shares beneficially owned.

The filing also discloses the cancellation of 153,731 stock options with strike prices between $2.01 and $21.95 that were at or above the per-share merger consideration; these options were terminated for no consideration.

No open-market trades, pricing data, or new financial metrics are included—this is a procedural disclosure linked solely to the completed merger.

Key take-aways from the Form 4 filed for Akoya Biosciences (AKYA)

• Reporting person: Director Myla Lai-Goldman.
• Transaction date: 07/08/2025, which is the closing date of the merger between Akoya Biosciences and Quanterix Corporation.
• Merger mechanics: Each outstanding AKYA common share was converted into (a) 0.1461 share of Quanterix common stock and (b) $0.38 in cash (together, the “Per Share Merger Consideration”). The consideration may be adjusted under the Merger Agreement.
• Common shares disposed: 20,000 AKYA shares were relinquished under Transaction Code J (other). The director now reports 0 AKYA shares beneficially owned.
• Stock options cancelled: Four tranches of options (38,993 @ $18.10; 30,549 @ $11.24; 56,322 @ $5.70; 50,000 @ $2.01) were accelerated and automatically terminated for no consideration, in line with the merger terms, because their exercise prices equalled or exceeded the merger consideration. Total options affected: 175,864.
• Post-merger structure: Akoya survives as a wholly-owned subsidiary of Quanterix, and AKYA securities cease to exist as standalone equity.

The filing is strictly a compliance disclosure reflecting the consummation of the merger and the resulting elimination of the director’s direct holdings in AKYA equity instruments.

Key take-aways from the Form 4 filed for Akoya Biosciences (AKYA)

• Reporting person: Director Myla Lai-Goldman.
• Transaction date: 07/08/2025, which is the closing date of the merger between Akoya Biosciences and Quanterix Corporation.
• Merger mechanics: Each outstanding AKYA common share was converted into (a) 0.1461 share of Quanterix common stock and (b) $0.38 in cash (together, the “Per Share Merger Consideration”). The consideration may be adjusted under the Merger Agreement.
• Common shares disposed: 20,000 AKYA shares were relinquished under Transaction Code J (other). The director now reports 0 AKYA shares beneficially owned.
• Stock options cancelled: Four tranches of options (38,993 @ $18.10; 30,549 @ $11.24; 56,322 @ $5.70; 50,000 @ $2.01) were accelerated and automatically terminated for no consideration, in line with the merger terms, because their exercise prices equalled or exceeded the merger consideration. Total options affected: 175,864.
• Post-merger structure: Akoya survives as a wholly-owned subsidiary of Quanterix, and AKYA securities cease to exist as standalone equity.

The filing is strictly a compliance disclosure reflecting the consummation of the merger and the resulting elimination of the director’s direct holdings in AKYA equity instruments.

Key take-aways from the Form 4 filed for Akoya Biosciences (AKYA)

• Reporting person: Director Myla Lai-Goldman.
• Transaction date: 07/08/2025, which is the closing date of the merger between Akoya Biosciences and Quanterix Corporation.
• Merger mechanics: Each outstanding AKYA common share was converted into (a) 0.1461 share of Quanterix common stock and (b) $0.38 in cash (together, the “Per Share Merger Consideration”). The consideration may be adjusted under the Merger Agreement.
• Common shares disposed: 20,000 AKYA shares were relinquished under Transaction Code J (other). The director now reports 0 AKYA shares beneficially owned.
• Stock options cancelled: Four tranches of options (38,993 @ $18.10; 30,549 @ $11.24; 56,322 @ $5.70; 50,000 @ $2.01) were accelerated and automatically terminated for no consideration, in line with the merger terms, because their exercise prices equalled or exceeded the merger consideration. Total options affected: 175,864.
• Post-merger structure: Akoya survives as a wholly-owned subsidiary of Quanterix, and AKYA securities cease to exist as standalone equity.

The filing is strictly a compliance disclosure reflecting the consummation of the merger and the resulting elimination of the director’s direct holdings in AKYA equity instruments.